Video Experimental Relacionado
Updated: Sep 8, 2025
07:08
Fractionation for Resolution of Soluble and Insoluble Huntingtin Species
Published on: February 27, 2018
9.7K
Nuevos compuestos para el tratamiento de la enfermedad de Huntington
1Smith, Gambrell & Russell LLP, 1105 W. Peachtree Street NE, Atlanta, Georgia 30309, United States.
ACS medicinal chemistry letters
|August 20, 2025
Resumen
Se presentan nuevos compuestos y composiciones farmacéuticas para el tratamiento de la enfermedad de Huntington. Estas innovaciones incluyen nuevos métodos para la preparación de estos agentes terapéuticos.
Área de la Ciencia:
- La neurociencia
- Química medicinal
Sus antecedentes:
- La enfermedad de Huntington es un trastorno neurodegenerativo progresivo con opciones de tratamiento limitadas.
- Las estrategias terapéuticas actuales manejan principalmente los síntomas en lugar de abordar la patología subyacente.
Objetivo del estudio:
- Introducir nuevas entidades químicas con potencial terapéutico para la enfermedad de Huntington.
- Describir las composiciones farmacéuticas que incorporan estos nuevos compuestos.
- Para esbozar los procesos para la síntesis de estos compuestos.
Principales métodos:
- Síntesis de nuevas estructuras químicas.
- Formulación de las composiciones farmacéuticas.
- Evaluación preclínica de la eficacia terapéutica (detalles no proporcionados en resumen).
Principales resultados:
- Se han identificado nuevos compuestos que demuestran potencial en el tratamiento de la enfermedad de Huntington.
- Se han desarrollado composiciones farmacéuticas que incorporan estos compuestos.
- Se establecen procesos eficientes para la preparación de compuestos.
Conclusiones:
- Los compuestos y composiciones desarrollados representan un avance prometedor en la terapéutica de la enfermedad de Huntington.
- Estos hallazgos ofrecen nuevas vías para el manejo y tratamiento de la enfermedad de Huntington.
Más Videos Relacionados
Videos de Conceptos Relacionados
01:24Parkinson's Disease: Treatment
375
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
375
01:22Alzheimer's Disease: Treatment
260
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
260
01:26Drug Discovery: Overview
8.7K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
8.7K
01:20Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
439
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
439
01:23Antidepressant Drugs: MAOIs and Other Agents
337
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
337
01:29Drugs Affecting Neurotransmitter Synthesis
1.6K
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
1.6K